Literature DB >> 11505070

Bactericidal/permeability-increasing protein attenuates systemic inflammation and acute lung injury in porcine lower limb ischemia-reperfusion injury.

D W Harkin1, A A Barros D'Sa, K McCallion, M Hoper, M I Halliday, F C Campbell.   

Abstract

OBJECTIVE: To investigate the role of recombinant bactericidal/permeability-increasing protein (rBPI21) in the attenuation of the sepsis syndrome and acute lung injury associated with lower limb ischemia-reperfusion (I/R) injury. SUMMARY BACKGROUND DATA: Gut-derived endotoxin has been implicated in the conversion of the sterile inflammatory response to a lethal sepsis syndrome after lower torso I/R injury. rBPI21 is a novel antiendotoxin therapy with proven benefit in sepsis.
METHODS: Anesthetized ventilated swine underwent midline laparotomy and bilateral external iliac artery occlusion for 2 hours followed by 2.5 hours of reperfusion. Two groups (n = 6 per group) were randomized to receive, by intravenous infusion over 30 minutes, at the start of reperfusion, either thaumatin, a control-protein preparation, at 2 mg/kg body weight, or rBPI21 at 2 mg/kg body weight. A control group (n = 6) underwent laparotomy without further treatment and was administered thaumatin at 2 mg/kg body weight after 2 hours of anesthesia. Blood from a carotid artery cannula was taken every half-hour for arterial blood gas analysis. Plasma was separated and stored at -70 degrees C for later determination of plasma tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 by bioassay, and IL-8 by enzyme-linked immunosorbent assay (ELISA), as a markers of systemic inflammation. Plasma endotoxin concentration was measured using ELISA. Lung tissue wet-to-dry weight ratio and myeloperoxidase concentration were used as markers of edema and neutrophil sequestration, respectively. Bronchoalveolar lavage protein concentration was measured by the bicinclinoic acid method as a measure of capillary-alveolar protein leak. The alveolar-arterial gradient was measured; a large gradient indicated impaired oxygen transport and hence lung injury.
RESULTS: Bilateral hind limb I/R injury increased significantly intestinal mucosal acidosis, intestinal permeability, portal endotoxemia, plasma IL-6 concentrations, circulating phagocytic cell priming and pulmonary leukosequestration, edema, capillary-alveolar protein leak, and impaired gas exchange. Conversely, pigs treated with rBPI21 2 mg/kg at the onset of reperfusion had significantly reduced intestinal mucosal acidosis, portal endotoxin concentrations, and circulating phagocytic cell priming and had significantly less pulmonary edema, leukosequestration, and respiratory failure.
CONCLUSIONS: Endotoxin transmigration across a hyperpermeable gut barrier, phagocytic cell priming, and cytokinemia are key events of I/R injury, sepsis, and pulmonary dysfunction. This study shows that rBPI21 ameliorates these adverse effects and may provide a novel therapeutic approach for prevention of I/R-associated sepsis syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505070      PMCID: PMC1422011          DOI: 10.1097/00000658-200108000-00014

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  55 in total

Review 1.  Pathophysiology of ischaemia reperfusion injury: central role of the neutrophil.

Authors:  C R Welbourn; G Goldman; I S Paterson; C R Valeri; D Shepro; H B Hechtman
Journal:  Br J Surg       Date:  1991-06       Impact factor: 6.939

2.  Acute lung injury following reperfusion after ischemia in the hind limbs of rats.

Authors:  J Punch; R Rees; B Cashmer; K Oldham; E Wilkins; D J Smith
Journal:  J Trauma       Date:  1991-06

3.  Thromboxane mediates diapedesis after ischemia by activation of neutrophil adhesion receptors interacting with basally expressed intercellular adhesion molecule-1.

Authors:  G Goldman; R Welbourn; J M Klausner; C R Valeri; D Shepro; H B Hechtman
Journal:  Circ Res       Date:  1991-04       Impact factor: 17.367

4.  Evidence for tumor necrosis factor-induced pulmonary microvascular injury after intestinal ischemia-reperfusion injury.

Authors:  M G Caty; K S Guice; K T Oldham; D G Remick; S I Kunkel
Journal:  Ann Surg       Date:  1990-12       Impact factor: 12.969

5.  Endotoxaemia, the generation of the cytokines and their relationship to intramucosal acidosis of the sigmoid colon in elective abdominal aortic aneurysm repair.

Authors:  C V Soong; P H Blair; M I Halliday; M D McCaigue; G R Campbell; J M Hood; B J Rowlands; A A Barros D'Sa
Journal:  Eur J Vasc Surg       Date:  1993-09

6.  Role of neutrophil adherence receptors (CD 18) in lung permeability following lower torso ischemia.

Authors:  R Welbourn; G Goldman; L Kobzik; I S Paterson; C R Valeri; D Shepro; H B Hechtman
Journal:  Circ Res       Date:  1992-07       Impact factor: 17.367

7.  Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria.

Authors:  J Weiss; P Elsbach; C Shu; J Castillo; L Grinna; A Horwitz; G Theofan
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

8.  Portal endotoxin and cytokine responses during abdominal aortic surgery.

Authors:  R J Baigrie; P M Lamont; S Whiting; P J Morris
Journal:  Am J Surg       Date:  1993-09       Impact factor: 2.565

9.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

10.  A recombinant amino terminal fragment of bactericidal/permeability-increasing protein inhibits the induction of leukocyte responses by LPS.

Authors:  K Mészáros; J B Parent; H Gazzano-Santoro; R Little; A Horwitz; T Parsons; G Theofan; L Grinna; J Weickmann; P Elsbach
Journal:  J Leukoc Biol       Date:  1993-12       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.